Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 20 min ago
Peer-reviewedCC BY-NC-NDTranslational Lung Cancer Research

Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study

  • Jiajie Sun1
  • Xinjing Li2
  • Bingxue Wang3
  • Zhangxuan Chen3
  • Yang Yao3
  • Ranpu Wu4
  • Xiaohua Pan5
  • Xuanhao Xu6
  • Yunxiao Si6
  • Hongbing Liu6
6 affiliations
  1. 1Department of Respiratory and Critical Care Medicine , Jinling Clinical Medical College , Nanjing Medical University , Nanjing , ;
  2. 2Department of Respiratory and Critical Care Medicine , Jinling Clinical Medical College , Nanjing University of Chinese Medicine , Nanjing , ;
  3. 3Department of Respiratory and Critical Care Medicine , Jinling Hospital , Affiliated Hospital of Medical School , Nanjing University , Nanjing , ;
  4. 4Department of Respiratory and Critical Care Medicine , Jinling Hospital , Southeast University School of Medicine , Nanjing , ;
  5. 5School of Basic Medicine and Clinical Pharmacy , China Pharmaceutical University , Nanjing ,
  6. 6Department of Respiratory and Critical Care Medicine , The Second Affiliated Hospital of Nanjing Medical University , Nanjing , ;
Read full textPDFCite

Related

  1. Comparative effectiveness of first-/second-generation EGFR-TKI combination therapy versus third-generation EGFR-TKI monotherapy in untreated locally advanced or metastatic EGFR-mutant NSCLC: a real-world, retrospective study in China
    Xinwei Wu, Danni Wang, Yangbin Shi +8
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  2. Temporal and therapeutic confounders in predicting efficacy of immunotherapy rechallenge via baseline intratumoral tertiary lymphoid structures.
    Anran Sun, Hongkai Chen, Anyang Wei
    Journal for immunotherapy of cancerPeer-reviewedCC BY-NCFull textOncologyEurope PMC
  3. Final efficacy and safety data from the Phase I/II ARROW study of pralsetinib in patients with advanced REarranged during Transfection fusion-positive non-small cell lung cancer.
    Robert Roskoski
    Journal of thoracic diseasePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. 1180 Interim safety and efficacy results of Victoria-01: a phase 1 study to evaluate the safety and preliminary efficacy of SOT201 in patients with advanced/metastatic solid tumors
    Radka Obermannova, Aung Naing, Hans Prenen +11
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ
  5. Efficacy and safety of narlumosbart in combination with stereotactic body radiation therapy followed by first-line chemotherapy combined with immunotherapy in advanced driver gene-negative non-small cell lung cancer patients with bone metastases: a phase II, single-arm, single-centre clinical trial protocol
    Jin Li, Nianlan Zhou, Saiquan Lu +4
    BMJ OpenPeer-reviewedCC BY-NC 4.0Full textGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{sun2026efficacy,
  title = {{Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study}},
  author = {Jiajie Sun and Xinjing Li and Bingxue Wang and Zhangxuan Chen and Yang Yao and Ranpu Wu and Xiaohua Pan and Xuanhao Xu and Yunxiao Si and Hongbing Liu},
  journal = {Translational Lung Cancer Research},
  year = {2026},
  month = aug,
  url = {https://europepmc.org/article/PMC/PMC13657885},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Efficacy and safety of third-generation EGFR-TKI rechallenge therapy in advanced non-small cell lung cancer patients with EGFR mutation: a retrospective cohort study
AU  - Jiajie Sun
AU  - Xinjing Li
AU  - Bingxue Wang
AU  - Zhangxuan Chen
AU  - Yang Yao
AU  - Ranpu Wu
AU  - Xiaohua Pan
AU  - Xuanhao Xu
AU  - Yunxiao Si
AU  - Hongbing Liu
PY  - 2026
DA  - 2026/08/13
JO  - Translational Lung Cancer Research
UR  - https://europepmc.org/article/PMC/PMC13657885
SN  - 2218-6751
ER  -